EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD–MBD) biomarkers in nephrology practices

Maria Fusaro iD, Simona Barbuto, Maurizio Gallieni iD, Althea Cossettini, Giulia Vanessa Re Sartò, Laura Cosmai iD, Giuseppe Cianciolo, Gaetano La Manna, Thomas Nickolas iD, Serge Ferrari iD, Jordi Bover, Mathias Haarhaus und 13 weitere

Clinical Kidney Journal · 04.01.2024 · 17 (1)

DOI: 10.1093/ckj/sfad290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 29.11.2023. Verfasst von Maria Fusaro und 24 weiteren Autor:innen. Beteiligte Einrichtung: National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic kidney disease mineral bone disorder (CKD-MBD) is a condition characterized by alterations of calcium, phosphate, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF-23) metabolism that in turn promote bone disorders, vascular calcifications, and increase cardiovascular (CV) risk. Nephrologists’ awareness of diagnostic, prognostic, and therapeutic tools to manage CKD-MBD plays a primary role in adequately preventing and managing this condition in clinical practice.

Methods

A national survey (composed of 15 closed questions) was launched to inquire about the use of bone biomarkers in the management of CKD-MBD patients by nephrologists and to gain knowledge about the implementation of guideline recommendations in clinical practice.

Results

One hundred and six Italian nephrologists participated in the survey for an overall response rate of about 10%. Nephrologists indicated that the laboratories of their hospitals were able to satisfy request of ionized calcium levels, 105 (99.1%) of both PTH and alkaline phosphatase (ALP), 100 (94.3%) of 25(OH)D, and 61 (57.5%) of 1.25(OH)2D; while most laboratories did not support the requests of biomarkers such as FGF-23 (intact: 88.7% and c-terminal: 93.4%), Klotho (95.3%; soluble form: 97.2%), tartrate-resistant acid phosphatase 5b (TRAP-5b) (92.5%), C-terminal telopeptide (CTX) (71.7%), and pro-collagen type 1 N-terminal pro-peptide (P1NP) (88.7%). As interesting data regarding Italian nephrologists’ behavior to start treatment of secondary hyperparathyroidism (sHPT), the majority of clinicians used KDOQI guidelines (n = 55, 51.9%). In contrast, only 40 nephrologists (37.7%) relied on KDIGO guidelines, which recommended referring to values of PTH between two and nine times the upper limit of the normal range.

Conclusion

Results point out a marked heterogeneity in the management of CKD-MBD by clinicians as well as a suboptimal implementation of guidelines in Italian clinical practice.

Schlagwörter

Stichwörter der Autor:innen

CKD-MBDbone biomarkersbone fracturesbone turnover markersvascular calcifications

Autor:innen und Institutionen

  • National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy.
  • Department of Medicine, University of Padova, Padova, Italy.
  • Nephrology, Dialysis and Renal Transplant Unit, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università di Milano, Milano, Italy.
  • Post-Graduate School of Specialization in Nephrology, University of Milano, Milano, Italy.
  • Division of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco, Fatebenefratelli Hospital, Milan, Italy.

ORCID-Profile: Maria Fusaro, Maurizio Gallieni, Laura Cosmai, Thomas Nickolas, Serge Ferrari, Mario Plebani, Mario Cozzolino, Piergiorgio Messa

Zitieren

APA

Fusaro, M., Barbuto, S., Gallieni, M., Cossettini, A., Re Sartò, G. V., Cosmai, L., Cianciolo, G., La Manna, G., Nickolas, T., Ferrari, S., Bover, J., Haarhaus, M., Marino, C., Mereu, M. C., Ravera, M., Plebani, M., Zaninotto, M., Cozzolino, M., Bianchi, S., …, & Tripepi, G. (2024). Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD–MBD) biomarkers in nephrology practices. Clinical Kidney Journal, 17(1). https://doi.org/10.1093/ckj/sfad290

Vancouver

Fusaro M, Barbuto S, Gallieni M, Cossettini A, Re Sartò GV, Cosmai L, et al. Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD–MBD) biomarkers in nephrology practices. Clinical Kidney Journal. 2024;17(1). doi:10.1093/ckj/sfad290

BibTeX
@article{Fusaro2024,
  author = {Fusaro, Maria and Barbuto, Simona and Gallieni, Maurizio and Cossettini, Althea and Re Sartò, Giulia Vanessa and Cosmai, Laura and Cianciolo, Giuseppe and La Manna, Gaetano and Nickolas, Thomas and Ferrari, Serge and Bover, Jordi and Haarhaus, Mathias and Marino, Carmela and Mereu, Maria Cristina and Ravera, Maura and Plebani, Mario and Zaninotto, Martina and Cozzolino, Mario and Bianchi, Stefano and Messa, Piergiorgio and Gregorini, Mariacristina and Gasperoni, Lorenzo and Agosto, Caterina and Aghi, Andrea and Tripepi, Giovanni},
  title = {Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD–MBD) biomarkers in nephrology practices},
  journal = {Clinical Kidney Journal},
  year = {2024},
  volume = {17},
  number = {1},
  doi = {10.1093/ckj/sfad290}
}
Kostenlos starten →